Skinvisible Inc (SKVI) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
6320 S SANDHILL ROAD LAS VEGAS, NV 89120 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 6/30/2025 Q2 | 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 13 | 10 | 1 | 7 | 8 | 1 | |||
| Cash and cash equivalent | 13 | 10 | 1 | 7 | 8 | 1 | |||
| Receivables | 0 | 5 | 1 | 5 | 5 | 27 | |||
| Other undisclosed current assets | 24 | 27 | 26 | 24 | 18 | 8 | |||
| Total current assets: | 38 | 42 | 27 | 36 | 31 | 35 | |||
| Noncurrent Assets | |||||||||
| Intangible assets, net (including goodwill) | 111 | 116 | 121 | 127 | 123 | 127 | |||
| Intangible assets, net (excluding goodwill) | 111 | 116 | 121 | 127 | 123 | 127 | |||
| Total noncurrent assets: | 111 | 116 | 121 | 127 | 123 | 127 | |||
| TOTAL ASSETS: | 150 | 158 | 149 | 163 | 153 | 163 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 959 | 859 | 1,150 | 660 | 533 | 439 | |||
| Accrued liabilities | 2,926 | 2,785 | 2,642 | 2,873 | 2,729 | 2,576 | |||
| Other undisclosed accounts payable and accrued liabilities | (1,967) | (1,926) | (1,491) | (2,213) | (2,196) | (2,137) | |||
| Debt | 9 | 13 | 9 | 4 | 3 | 6 | |||
| Other undisclosed current liabilities | 3,288 | 2,807 | 3,484 | 3,360 | 3,559 | 3,068 | |||
| Total current liabilities: | 4,257 | 3,680 | 4,644 | 4,024 | 4,094 | 3,512 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 5,372 | 5,372 | 5,372 | 5,372 | 5,372 | 5,372 | |||
| Long-term debt, excluding current maturities | 5,372 | 5,372 | 5,372 | 5,372 | 5,372 | 5,372 | |||
| Other undisclosed noncurrent liabilities | 352 | 349 | 301 | ||||||
| Total noncurrent liabilities: | 5,372 | 5,724 | 5,372 | 5,721 | 5,372 | 5,674 | |||
| Total liabilities: | 9,629 | 9,404 | 10,016 | 9,745 | 9,467 | 9,186 | |||
| Equity | |||||||||
| Equity, attributable to parent | (9,480) | (9,246) | (9,867) | (9,582) | (9,313) | (9,023) | |||
| Common stock | 5 | 5 | 5 | 5 | 5 | 5 | |||
| Additional paid in capital | 30,742 | 30,685 | 30,388 | 30,388 | 30,353 | 30,353 | |||
| Accumulated deficit | (40,227) | (39,946) | (40,261) | (39,974) | (39,671) | (39,380) | |||
| Other additional capital | 10 | 1 | |||||||
| Total equity: | (9,480) | (9,246) | (9,867) | (9,582) | (9,313) | (9,023) | |||
| TOTAL LIABILITIES AND EQUITY: | 150 | 158 | 149 | 163 | 153 | 163 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 6/30/2025 Q2 | 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 5 | 5 | 5 | 5 | 5 | 5 | ||
| Other income | ||||||||
| Gross profit: | 5 | 5 | 5 | 5 | 5 | 5 | ||
| Operating expenses | (145) | (204) | (130) | (148) | (128) | (142) | ||
| Other operating expense, net (Other Expenses) | (167) | |||||||
| Other undisclosed operating income | 167 | |||||||
| Operating loss: | (140) | (199) | (125) | (143) | (123) | (137) | ||
| Interest and debt expense | (168) | |||||||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 697 | |||||||
| Net income (loss): | (140) | 499 | (125) | (143) | (123) | (304) | ||
| Other undisclosed net income (loss) attributable to parent | (141) | (184) | (162) | (161) | (167) | 1 | ||
| Net income (loss) available to common stockholders, diluted: | (281) | 315 | (287) | (303) | (290) | (304) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 6/30/2025 Q2 | 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (140) | 499 | (125) | (143) | (123) | (304) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (140) | 499 | (125) | (143) | (123) | (304) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.